Inter Pharma Public Company Limited

As of June 30, 2026, Inter Pharma Public Company Limited NVDR carries a market capitalization of 2.70B, placing it among publicly traded companies globally. Its enterprise value stands at 3.07B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Inter Pharma Public Company Limited NVDR's next confirmed earnings release is scheduled for November 17, 2026.

As of June 30, 2026, Inter Pharma Public Company Limited NVDR has 605.34M shares outstanding.

As of June 30, 2026, Inter Pharma Public Company Limited NVDR trades at a trailing price-to-earnings ratio of 19.57. The price-to-sales ratio is 1.20, and the price-to-book ratio stands at 1.30.

As of June 30, 2026, Inter Pharma Public Company Limited NVDR trades at an EV/EBITDA multiple of 9.09 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.37 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 14.17 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Inter Pharma Public Company Limited NVDR trades at an EV/FCF ratio of 22.82, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 3.07B versus a market cap of 2.70B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Inter Pharma Public Company Limited NVDR maintains a current ratio of 1.79, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 15.57, indicating elevated leverage, while an interest coverage ratio of 19.69 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Inter Pharma Public Company Limited NVDR posted a return on equity (ROE) of 6.77, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 6.41 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.32, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 5.00, useful for judging operating efficiency across full business cycles. The company generates approximately 9.92M in revenue per employee across its workforce of 226.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.39 indicates how many times Inter Pharma Public Company Limited NVDR sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Inter Pharma Public Company Limited NVDR recorded 42.61M in income tax expense. That works out to an effective tax rate of 21.48, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 198.34M, leaving 137.99M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Inter Pharma Public Company Limited NVDR's stock has gained approximately 31.55% over the past 52 weeks. The 50-day moving average sits at 5.02, while the 200-day moving average is 4.55.

Over the twelve months ended June 30, 2026, Inter Pharma Public Company Limited NVDR generated 2.24B in revenue and converted that into 137.99M in net income, yielding earnings per share of 0.26. EBITDA reached 337.79M, while operating income came in at 216.69M.

As of June 30, 2026, Inter Pharma Public Company Limited NVDR holds 242.71M in cash and equivalents against 363.23M in total debt, resulting in a net debt position of 42.15M. Total book value stands at 2.08B, with working capital of 497.96M providing operational flexibility.

Inter Pharma Public Company Limited NVDR produced 239.95M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -118.90M in capital expenditures, free cash flow totaled 121.05M - equivalent to 0.20 per share.

Over the twelve months ended June 30, 2026, Inter Pharma Public Company Limited NVDR posted a gross margin of 42.46, reflecting its pricing power and cost economics. The operating margin of 9.66 and net profit margin of 6.15 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Inter Pharma Public Company Limited NVDR paid dividends of 0.07 per share. The dividend payout ratio of 25.45 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 4.48, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 5.35, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Inter Pharma Public Company Limited NVDR shareholders.

Inter Pharma Public Company Limited NVDR's most recent stock split took place on May 7, 2024 with a 8:13 split ratio.

As of June 30, 2026, Inter Pharma Public Company Limited NVDR has an Altman Z-Score of 3.36, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.